| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CBP; EIF4F; EIF4E1; EIF4EL1; MGC111573; EIF4E |
| Entrez GeneID | 1977 |
| clone | 5D11 |
| WB Predicted band size | 25kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human EIF4E expressed in E. Coli. |
| Formulation | Ascitic fluid containing 0.03% sodium azide. |
+ +
以下是关于IGFBPL1抗体的3篇参考文献的简要信息：
1. **文献名称**：*IGFBPL1 regulates axon growth and guidance during zebrafish development*
**作者**：Li Y, et al.
**摘要**：该研究利用斑马鱼模型，发现IGFBPL1蛋白通过调控胰岛素样生长因子信号通路参与轴突生长和导向。研究中使用特异性IGFBPL1抗体进行免疫荧光染色，证实其在神经系统发育中的表达模式及功能缺失导致的轴突异常。
2. **文献名称**：*IGFBPL1 as a novel tumor suppressor in hepatocellular carcinoma*
**作者**：Wang X, et al.
**摘要**：本文通过免疫组化(使用IGFBPL1抗体)和分子实验，发现IGFBPL1在肝癌组织中表达下调，其低表达与患者预后不良相关。功能研究表明，IGFBPL1通过抑制PI3K/AKT通路抑制肿瘤细胞增殖和迁移。
3. **文献名称**：*Proteomic identification of IGFBPL1 as a biomarker for metabolic syndrome*
**作者**：Chen L, et al.
**摘要**：该研究通过蛋白质组学分析结合IGFBPL1抗体的Western blot验证，发现IGFBPL1在代谢综合征患者血清中显著降低，提示其可能作为代谢紊乱的潜在生物标志物，并参与脂肪代谢调控。
(注：以上文献为示例，实际文献需根据具体数据库检索结果确认。)
The IGFBPL1 (Insulin-like growth factor binding protein-like 1) antibody is a tool used to detect and study the IGFBPL1 protein, a member of the insulin-like growth factor binding protein (IGFBP) family. IGFBPL1 shares structural homology with IGFBPs, which regulate IGF bioavailability and signaling, but its precise biological role remains less characterized. Emerging evidence suggests IGFBPL1 may influence cellular processes such as proliferation, apoptosis, and metabolism, potentially interacting with pathways beyond the IGF axis, including extracellular matrix remodeling and immune regulation.
This antibody is primarily utilized in research applications like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to map IGFBPL1 expression patterns in tissues or cell lines. Studies have reported its involvement in diseases, including certain cancers (e.g., breast, liver) and metabolic disorders, where altered IGFBPL1 levels correlate with pathological progression. Commercial IGFBPL1 antibodies are typically raised in hosts like rabbits or mice, targeting specific epitopes within the protein’s conserved regions. Validation data, including knockout controls or siRNA silencing, are critical to confirm antibody specificity due to potential cross-reactivity with other IGFBP family members. Ongoing research aims to clarify IGFBPL1’s mechanistic roles and therapeutic potential, driving demand for reliable detection tools.
×
